Skyline Diagnostics, a developer of array-based diagnostic tests, has entered into a research agreement to discover a biomarker for Clavis Pharma's investigational Leukemia drug elacytarabine.

Elacytarabine, an elaidic acid derivative of cytarabine which is used to treat patients with relapsed or refractory acute myeloid leukemia (AML) is undergoing the Clavela phase III study.

As per the agreement, Skyline will look into gene expression biomarkers for selection of individual AML patients who may benefit from a new AML drug.

Clavis Pharma CMO Athos Gianella-Borradori said this genomic approach adds to their currently ongoing patient selection based on protein markers and will deepen their insights into the potential for effective personalized medicines.